ECRD 2026: Navigating the rare disease diagnostic and drug development maze
While rare disease research has advanced significantly, related expertise and data are scattered across too many disconnected places.
Healthcare
ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment
Huntington’s gene therapy research has reached a turning point, expert says
Calls for change as access to cell and gene therapies in the Netherlands falls short
Autologous versus allogeneic: how cell therapy development is changing in oncology
SLE and LN market expected to reach $5.9bn across 7MM by 2034
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
